Antibodies News and Research

RSS

New mathematical model predicts biological process that creates antibody diversity

Scientists at USC have created a mathematical model that explains and predicts the biological process that creates antibody diversity - the phenomenon that keeps us healthy by generating robust immune systems through hypermutation.

9 Oct 2013

New HIV vaccines stimulate critical immune response in infants born to HIV-infected mothers

A new analysis of two HIV vaccine trials that involved pediatric patients shows that the investigational vaccines stimulated a critical immune response in infants born to HIV-infected mothers, researchers at Duke Medicine report.

9 Oct 2013

Researchers use ARRAYit Microarray Platform to discover important biomarkers

ARRAYit Corporation reports today that researchers at the National Institutes of Health (NIH), National Cancer Institute (NCI) and Northeastern University have used the ARRAYit Microarray Platform to discover biomarkers important in the treatment of prostate cancer.

8 Oct 2013

Scientists devised technique to make antibody-drug conjugates, basis of new therapies

Chemists at The Scripps Research Institute (TSRI) have devised a new technique for connecting drug molecules to antibodies to make advanced therapies.

8 Oct 2013

Scientists at Oklahoma Medical Research Foundation identify six new Sj-gren-related genes

With the completion of the first genome-wide association study for Sj-gren's syndrome, an international coalition of researchers led by scientists at the Oklahoma Medical Research Foundation has identified six new disease-related genes.

7 Oct 2013

EMD Serono announces recipients of company's inaugural Grant for Multiple Sclerosis Innovation

EMD Serono, Inc., a subsidiary of Merck KGaA, Darmstadt, Germany, announced today on the occasion of the 29th European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), the recipients of the company's inaugural Grant for Multiple Sclerosis Innovation (GMSI).

7 Oct 2013

New classification criteria for systemic sclerosis published in ACR journal

New classification criteria for systemic sclerosis have just been published and are more sensitive than the 1980 criteria, enabling earlier identification and treatment of this disabling autoimmune disease.

3 Oct 2013

Insulin interaction map could lead to new therapeutic targets for type 2 diabetes

A team led by scientists at The Scripps Research Institute has created the first comprehensive roadmap of the protein interactions that enable cells in the pancreas to produce, store and secrete the hormone insulin. The finding makes possible a deeper scientific understanding of the insulin secretion process—and how it fails in insulin disorders such as type 2 diabetes.

1 Oct 2013

Roadmap of protein interactions may lead to new therapeutic approaches for type 2 diabetes

A team led by scientists at The Scripps Research Institute (TSRI) has created the first comprehensive roadmap of the protein interactions that enable cells in the pancreas to produce, store and secrete the hormone insulin.

1 Oct 2013

Pfizer Licenses Gliknik's Pooled IVIG In $25M+ Deal

...

30 Sep 2013

Immunologic checkpoint inhibitor shows promise in malignant mesothelioma

Tremelimumab, one of a new class of immunomodulatory monoclonal antibodies, has shown encouraging clinical activity and acceptable tolerability in patients with chemotherapy-resistant malignant mesothelioma, results of a single-arm phase II study show.

27 Sep 2013

T. gondii antibodies implicated in mania

Infection with Toxoplasma gondii may confer an increased risk for mania, say researchers.

26 Sep 2013

VolitionRx enters into distribution agreement with Active Motif for NuQ product line

VolitionRx Limited, a life sciences company focused on developing blood-based diagnostic tests for different types of cancer, today entered into an agreement with Active Motif, a leading provider of kits and reagents to enable epigenetics research.

26 Sep 2013

Pancreatic Cancer Imaging Agent Earns Mabvax $1.75M SBIR Award

...

24 Sep 2013

Inflammation tracks mania course

Markers of inflammation are elevated in patients who are hospitalized for acute mania, a study shows.

24 Sep 2013

Abbvie, Ablynx ink license agreement to develop anti-IL-6R Nanobody against inflammatory diseases

Ablynx and AbbVie today announced that they have entered into a global license agreement to develop and commercialize the anti-IL-6R Nanobody, ALX-0061, to treat inflammatory diseases.

23 Sep 2013

Scientists one step closer to developing universal flu vaccine

Scientists have moved closer to developing a universal flu vaccine after using the 2009 pandemic as a natural experiment to study why some people seem to resist severe illness.

23 Sep 2013

Antibody that binds, neutralizes HIV likely also targets the body's own self proteins

Researchers at The Scripps Research Institute discovered that an antibody that binds and neutralizes HIV likely also targets the body's own "self" proteins. This finding could complicate the development of HIV vaccines designed to elicit this protective antibody, called 4E10, and others like it, as doing so might be dangerous or inefficient.

20 Sep 2013

Scientists are preparing for possible pandemic spread of new bird flu strain

Scientists at Saint Louis University are preparing for the potential pandemic spread of a new bird flu strain that caused severe disease in China last spring, joining researchers from seven other Vaccine and Treatment Evaluation Units funded by the National Institutes of Health (NIH) to test vaccines to protect against the illness in adults.

20 Sep 2013

arGEN-X and Shire achieve milestone in SIMPLE Antibody R&D collaboration

arGEN-X, a clinical stage human monoclonal antibody therapeutics company, announces it has attained a key success milestone in its SIMPLE Antibody research and product development collaboration with the Human Genetic Therapies division of Shire Pharmaceuticals. The milestone, which triggered an undisclosed payment from Shire, was the first demonstration of in vivo proof of concept for one of the antibody discovery programs undertaken in the collaboration.

19 Sep 2013